acetylleucyl-leucyl-norleucinal has been researched along with tanshinone in 1 studies
| Studies (acetylleucyl-leucyl-norleucinal) | Trials (acetylleucyl-leucyl-norleucinal) | Recent Studies (post-2010) (acetylleucyl-leucyl-norleucinal) | Studies (tanshinone) | Trials (tanshinone) | Recent Studies (post-2010) (tanshinone) |
|---|---|---|---|---|---|
| 321 | 0 | 53 | 1,445 | 10 | 1,033 |
| Protein | Taxonomy | acetylleucyl-leucyl-norleucinal (IC50) | tanshinone (IC50) |
|---|---|---|---|
| Polycomb protein EED | Homo sapiens (human) | 8.9 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 4.75 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 2.21 | |
| Tyrosine-protein phosphatase non-receptor type 6 | Homo sapiens (human) | 1.97 | |
| Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens (human) | 2.57 | |
| Polycomb protein SUZ12 | Homo sapiens (human) | 8.9 | |
| Histone-lysine N-methyltransferase EZH2 | Homo sapiens (human) | 8.9 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 8.51 | |
| Endothelial PAS domain-containing protein 1 | Homo sapiens (human) | 8.51 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
1 other study(ies) available for acetylleucyl-leucyl-norleucinal and tanshinone
| Article | Year |
|---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |